Stocks Health care SEPN
NASDAQ · Health careSepterna, Inc. (SEPN)
Septerna, Inc. brought in $96.3M of revenue over the twelve months to September 30, 2026, up 336.7% from a year earlier. It posted a net loss of $59M. Operating cash flow minus capital spending left $109.7M of free cash flow in fiscal 2025. At September 30, 2026 it held $167.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Septerna, Inc.
- Net worth
- Septerna, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $427.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $46M (+4,174.5% year on year), with a net loss of $48.9M. Over the 12 months to September 30, 2026: revenue $96.3M, net loss $59M.
- Cash flow
- In fiscal 2025 operations brought in $110.2M of cash; after $518K of capital spending, free cash flow was $109.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Septerna, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Septerna, Inc. does
Septerna, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SEPN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $46M | -$48.9M | -$1.10 | $109.7M |
| 2024 | $1.1M | -$71.8M | -$7.26 | -$69.6M |
| 2024 | $151K | $4.2M | $0.29 | -$41.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SEPN ranks in Health care
Latest SEC filings
What Septerna, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 12% to $18.9M versus the same quarter last year; diluted EPS -$0.57 versus $0.18.
- November 9, 2026
- November 4, 2026
- August 25, 2026
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 22,376% to $26.7M versus the same quarter last year; diluted EPS -$0.29 versus -$0.56.
- August 10, 2026
- June 30, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 12,011% to $26.5M versus the same quarter last year; diluted EPS -$0.19 versus -$0.49.
What is SEPN worth? A DCF from its reported cash flow
Insider trades
What the people running Septerna, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $275.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Bhatt ElizabethPresident and COO | Exercised options | 4,000 | $27.2K |
| October 15, 2026 | Bhatt ElizabethPresident and COO | Soldpre-planned (10b5-1) | 1,094 | $40.3K |
| October 15, 2026 | Bhatt ElizabethPresident and COO | Soldpre-planned (10b5-1) | 2,906 | $109.3K |
| September 1, 2026 | Long Daniel D.SVP, Drug Discovery | Exercised options | 3,333 | $9.2K |
| September 1, 2026 | Long Daniel D.SVP, Drug Discovery | Soldpre-planned (10b5-1) | 3,333 | $126.1K |
| August 12, 2026 | Third Rock Ventures V, L.P.10% owner | Soldpre-planned (10b5-1) | 147,059 | $7.4M |
| August 12, 2026 | Third Rock Ventures V, L.P.10% owner | Soldpre-planned (10b5-1) | 141 | $7.2K |
| August 12, 2026 | Ra Capital Management, L.P.Director, 10% owner | Soldindirect | 746,500 | $31.7M |
Who owns SEPN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Third Rock Ventures V, L.P.13G, passive with 5 related filers | 14% | May 9, 2025 |
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 11.8% | August 14, 2026 |
| Driehaus Capital Management LLC13G, passive | 9.83% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 154 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 6,995,858 | 0 |
| Trv GP V, LLC | 6,215,591 | 0 |
| Driehaus Capital Management LLC | 4,433,058 | +37,486 |
| Trv GP VI, LLC | 4,211,659 | 0 |
| Samsara Biocapital, LLC | 3,149,128 | 0 |
| Goldman Sachs Group Inc | 3,062,766 | +156,339 |
| BlackRock, Inc. | 1,932,088 | +109,914 |
| Siren, L.L.C. | 1,900,000 | -100,000 |
| Avoro Capital Advisors LLC | 1,337,500 | 0 |
| Jupiter Topco LLC | 1,307,500 | new |
| Vanguard Capital Management LLC | 1,221,673 | +24,711 |
| Primecap Management Co | 1,167,382 | +118,548 |
| First Light Asset Management, LLC | 963,260 | +230,400 |
| ADAR1 Capital Management, LLC | 940,747 | -149,071 |
| Geode Capital Management, LLC | 679,163 | +34,017 |
| State Street Corp | 652,630 | +21,183 |
| Loomis Sayles & Co L P | 624,752 | new |
| Casdin Capital, LLC | 553,268 | 0 |
| Catalio Capital Management, LP | 536,152 | +241,792 |
| Algert Global LLC | 397,487 | +376,452 |
Insiders
5 insiders reported holding 7,065,248 shares in total, about $358.5M at the last price.
| Holder | Shares |
|---|---|
| Third Rock Ventures V, L.P.10% owner | 6,068,391 |
| Ra Capital Management, L.P.Director, 10% owner | 725,443725,443 held indirectly |
| Bhatt ElizabethPresident and COO | 174,209 |
| Long Daniel D.SVP, Drug Discovery | 96,412 |
| Shaikhly SamiraChief People Officer | 793 |
Questions about SEPN
What does Septerna, Inc. do?
Septerna, Inc. is a company in the Health care sector, listed on NASDAQ as SEPN. Its shares trade on NASDAQ under the ticker SEPN.
What is Septerna, Inc.'s net worth?
Septerna, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $427.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Septerna, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $59M on revenue of $96.3M.
How much revenue does Septerna, Inc. make?
Over the twelve months to September 30, 2026 Septerna, Inc. reported revenue of $96.3M. That is 336.7% more than a year earlier.
When did Septerna, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Septerna, Inc.'s next earnings report?
Septerna, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SEPN with
Follow SEPN
Get an email when Septerna, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Septerna, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.